Suzanne Samarani
Overview
Explore the profile of Suzanne Samarani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
548
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang L, Vulesevic B, Vigano M, Assadiq A, Kang K, Fernandez C, et al.
Vaccines (Basel)
. 2025 Jan;
12(12.
PMID: 39772034
HIV causes intense polyclonal activation of B cells, resulting in increased numbers of spontaneously antibody-secreting cells in the circulation and hypergammaglobulinemia. It is accompanied by significant perturbations in various B...
2.
Costiniuk C, Samarani S, Wang L, Vigano M, Ahmad A
Virologie (Montrouge)
. 2024 Sep;
28(4):255-276.
PMID: 39248670
While antiretroviral therapy (ART) has revolutionized the management of human immunodeficiency virus (HIV) and has enabled people living with HIV (PLWH) to achieve near-normal life expectancies, an HIV cure remains...
3.
Costiniuk C, Samarani S, Wang L, Vigano M, Ahmad A
Virologie (Montrouge)
. 2024 Sep;
28(4):1-20.
PMID: 39248668
While antiretroviral therapy (ART) has revolutionized the management of human immunodeficiency virus (HIV) and has enabled people living with HIV (PLWH) to achieve near-normal life expectancies, an HIV cure remains...
4.
Vigano M, Kubal S, Lu Y, Habib S, Samarani S, Cama G, et al.
Pharmaceuticals (Basel)
. 2024 Jul;
17(7).
PMID: 39065685
Chemotherapy-induced peripheral neuropathy (CIPN) remains a clinical challenge for up to 80% of breast cancer survivors. In an open-label study, participants underwent three interventions: standard care (duloxetine) for 1 month...
5.
Mboumba Bouassa R, Needham J, Nohynek D, Samarani S, Bobeuf F, Del Balso L, et al.
J Pers Med
. 2024 Jul;
14(7).
PMID: 39063999
Cannabis-based medicines (CBMs) could help reduce systemic inflammation in people with HIV (PWH). In a prospective, randomized pilot study we enrolled participants from August 2021-April 2022 with HIV, aged ≥18...
6.
Costiniuk C, Lee T, Singer J, Galipeau Y, Arnold C, Langlois M, et al.
Vaccines (Basel)
. 2024 May;
12(5).
PMID: 38793698
COVID-19 breakthrough infection (BTI) can occur despite vaccination. Using a multi-centre, prospective, observational Canadian cohort of people with HIV (PWH) receiving ≥2 COVID-19 vaccines, we compared the SARS-CoV-2 spike (S)...
7.
Costiniuk C, Singer J, Lee T, Galipeau Y, McCluskie P, Arnold C, et al.
AIDS
. 2023 Aug;
37(12):F25-F35.
PMID: 37534695
Objectives: Many vaccines require higher/additional doses or adjuvants to provide adequate protection for people with HIV (PWH). Here, we compare coronavirus disease 2019 (COVID-19) vaccine-induced antibody neutralization capacity in PWH...
8.
Mboumba Bouassa R, Comeau E, Alexandrova Y, Pagliuzza A, Yero A, Samarani S, et al.
Cells
. 2023 Jul;
12(14).
PMID: 37508476
Chronic HIV infection is characterized by persistent inflammation despite antiretroviral therapy (ART). Cannabinoids may help reduce systemic inflammation in people with HIV (PWH). To assess the effects of oral cannabinoids...
9.
Ahmad A, Samarani S, Costiniuk C
AIDS
. 2023 Jul;
37(10):1625-1627.
PMID: 37450628
No abstract available.
10.
Alexandrova Y, Yero A, Mboumba Bouassa R, Comeau E, Samarani S, Brumme Z, et al.
Viruses
. 2023 Feb;
15(2).
PMID: 36851789
People living with HIV (PLWH) may be at risk for poor immunogenicity to certain vaccines, including the ability to develop immunological memory. Here, we assessed T-cell immunogenicity following three SARS-CoV-2...